However, at closer inspection, these reactions were more likely caused by the (concomitant) use of angiotensin-converting enzyme inhibitors or an infection (130)
Kuckelman, senior vice president and group general counsel of global legal, IP, and security for Novo Nordisk, said, Throughout Novo Nordisks 103-year-long history, patient safety has always been our top priority
When patients experience fewer side effects, they are more likely to stay consistent with their treatment, which directly supports long-term adherence
For semaglutide, the relevant secondary patents include: Formulation patents covering the specific inactive ingredients, pH buffers, and stabilizers that keep semaglutide stable in solution (US 9,714,283, expires 2033) Method-of-use patents covering specific dosing schedules and titration protocols (US 10,195,214, expires 2032) Delivery device patents for the pen injector mechanism used in Ozempic and Wegovy (separate patent family, expires 2029-2031) Oral formulation patents for the SNAC (salcaprozate sodium) absorption enhancer used in Rybelsus tablets (US 9,931,349, expires 2032) The expiration date that matters to you depends on which formulation you care about
These medications commonly cause nausea, vomiting, and diarrhea, particularly during dose initiation and escalation